Summary
The highly anticipated arrival of hemophilia gene therapies has not lived up to expectations. One therapy has been pulled from the market while two others face challenges in obtaining reimbursement and widespread use. These difficulties are due to high prices, structural disincentives, and alternative treatment options.

Access impact
The high cost of gene therapies has led to pushback from payers, despite the potential long-term cost savings. Structural disincentives, such as the Hemophilia Treatment Center 340B Factor Program, also discourage adoption of gene therapies. Additionally, the availability of effective alternative treatments means that many patients can afford to wait and see. These challenges make it difficult for gene therapies to gain a foothold in the market.

Top-3 domain lens
Cost-Effectiveness
Gene therapies have a high price tag, leading to hesitation from payers and structural disincentives that discourage adoption.

Safety and Tolerability
While gene therapies offer the potential for long-term treatment, their durability and safety are still uncertain.

Clinical Effectiveness
The market for hemophilia gene therapies is facing challenges, despite the significant scientific innovation in this area.

Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug

CTA
If the article reports a concrete payer or HTA decision, guidance, policy, price action, or reimbursement status:
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Otherwise:
Follow MARA Rating for independent HTA insights: https://linkedin.com/company/mara-rating-company

Source
source: https://www.biopharmadive.com/news/hemophilia-gene-therapy-market-biomarin-csl-pfizer/807128/